Praxis Precision Medicines

Praxis Precision Medicines (PRAX) CEO Marcio Souza will participate in a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025, at 10:00 AM EST. The company focuses on developing therapies for central nervous system (CNS) disorders, specifically targeting neuronal excitation-inhibition imbalance using their Cerebrum™ and Solidus™ platforms. Praxis has a diversified CNS portfolio with four product candidates in clinical development.